5-Aminoimidazole-4-carboxamide ribonucleotide prevents fat gain following the cessation of voluntary physical activity

Exp Physiol. 2017 Nov 1;102(11):1474-1485. doi: 10.1113/EP086335. Epub 2017 Sep 19.

Abstract

What is the central question of this study? We investigated whether 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) could prevent acute increases in body fat and changes in omental and subcutaneous adipose tissue following the sudden transition from physical activity to physical inactivity. What is the main finding and its importance? AICAR prevented fat gains following the transition from physical activity to inactivity to levels comparable to rats that remained physically active. AICAR and continuous physical activity produced depot-specific changes in cyclin A1 mRNA and protein that were associated with the prevention of fat gain. These findings suggest that targeting AMP-activated protein kinase signalling could oppose rapid adipose mass growth. The transition from physical activity to inactivity is associated with drastic increases in 'catch-up' fat that in turn foster the development of many obesity-associated maladies. We tested whether 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) treatment would prevent gains in body fat following the sudden transition from a physically active state to an inactive state by locking a voluntary running wheel. Male Wistar rats were either sedentary (SED) or given wheel access for 4 weeks, at which time rats with wheels continued running (RUN), had their wheel locked (WL) or had WL with daily AICAR injection (WL + AICAR) for 1 week. RUN and WL + AICAR prevented gains in body fat compared with SED and WL (P < 0.001). Cyclin A1 mRNA, a marker of cell proliferation, was decreased in omental, but not subcutaneous adipose tissue, in RUN and WL + AICAR compared with SED and WL groups (P < 0.05). Both cyclin A1 mRNA and protein were positively associated with gains in fat mass (P < 0.05). Cyclin A1 mRNA in omental, but not subcutaneous, adipose tissue was negatively correlated with p-AMPK levels (P < 0.05). Differences in fat gain and omental mRNA and protein levels were independent of changes in food intake and in differences in select hypothalamic mRNAs. These findings suggest that AICAR treatment prevents acute gains in adipose tissue following physical inactivity to levels of rats that continuously run, and that together, continuous physical activity and AICAR could, at least initially in these conditions, exert similar inhibitory effects on adipogenesis in a depot-specific manner.

Keywords: AICAR; cyclin a1; physical inactivity; wheel lock.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Abdominal Fat / drug effects*
  • Abdominal Fat / metabolism
  • Adipogenesis / drug effects*
  • Adiposity / drug effects*
  • Aminoimidazole Carboxamide / analogs & derivatives*
  • Aminoimidazole Carboxamide / pharmacology
  • Animals
  • Anti-Obesity Agents / pharmacology*
  • Cyclin A1 / genetics
  • Cyclin A1 / metabolism
  • Enzyme Activation
  • Enzyme Activators / pharmacology
  • Hypothalamus / drug effects
  • Hypothalamus / metabolism
  • Male
  • Phosphorylation
  • Physical Conditioning, Animal / methods*
  • Physical Exertion
  • Rats, Wistar
  • Ribonucleotides / pharmacology*
  • Running
  • Sedentary Behavior*
  • Subcutaneous Fat / drug effects*
  • Subcutaneous Fat / metabolism
  • Time Factors
  • Volition
  • Weight Gain / drug effects*

Substances

  • Anti-Obesity Agents
  • Ccna1 protein, rat
  • Cyclin A1
  • Enzyme Activators
  • Ribonucleotides
  • Aminoimidazole Carboxamide
  • AMP-Activated Protein Kinases
  • AICA ribonucleotide